News

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...
The Lancet3h
Body composition during major incretin-based weight loss
We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...
Dynamic Export7h
GLP-1s Revolutionizing Mental Health: What This Means for Employees
GLP-1 agonists, or glucagon-like peptide-1 agonists, function by mimicking the action of a natural hormone in the body that helps regulate blood sugar levels and digestion. Originally developed for ...